Anumana Acquires NeuTrace, an AI-Electrophysiology Company

See Release

Anumana in the News

All Topics

Media Contact |


AI transforms smartwatch ECG signals into a diagnostic tool for heart failure

Mayo Clinic News Network: Two health tech advances are at the heart of a study published in Nature Medicine: an app and backend infrastructure to let patients remotely share smartwatch ECG data with their clinicians in an easy and secure way, and the modification of a proven 12-lead ECG artificial intelligence (AI) algorithm to enable it to run on a single-lead watch ECG recording.

November 14, 2022

NeuTrace Acquistion

Mayo Clinic spinout Anumana acquires NeuTrace to develop cardiac procedure AI

FIERCE Biotech: Mayo Clinic’s artificial intelligence spinout Anumana is taking a deeper dive into analyzing the pulsing electrical signals of the heart with a new acquisition aimed at developing software used during cardiac procedures.

November 8, 2022

NeuTrace Acquistion

Mayo Clinic Platform portfolio company buys AI electrophysiology startup

Becker's Hospital Review: Anumana, a portfolio company of Mayo Clinic Platform, has acquired NeuTrace, a medtech startup that applies artificial intelligence to electrophysiology. Anumana can now integrate a patient's entire EHR with corresponding electrocardiograms and cardiac electrograms.

November 8, 2022

NeuTrace Acquistion

Anumana Acquires NeuTrace, Establishing a Comprehensive Electrophysiology Deep-Learning Development Platform and Product Pipeline

AI Thority: Anumana, an AI-driven health technology company and portfolio company of nference, announced it has acquired NeuTrace, a medical technology company advancing novel in-procedure AI applications for electrophysiology (EP). The acquisition includes the NeuTrace EP Data Biome platform and a portfolio of AI-enabled EP software applications in development. As part of the transaction, nference acquired rights to the Data Biome platform for uses outside of the cardiovascular field.

November 8, 2022

NeuTrace Acquistion

Anumana acquires AI medical software provider NeuTrace

NS Medical Devices: Anumana said that the acquisition strengthens its position as a developer of AI medical software for cardiac EP, powered by nference’s nSights real-world evidence platform.

November 8, 2022

of 13

Partner with us!

We’re actively developing algorithms for FDA approval. Please direct partnership and media inquiries to

@2022 anumana, Inc. All rights reserved.